Straits Times Index
3,319.29 -2.79 (-0.08%) Nikkei
39,157.63 +119.47 (+0.31%) Hang Seng
18,129.65 -237.30 (-1.29%) FTSE 100
8,228.48 -16.89 (-0.20%) Bitcoin USD
69,384.94 -255.70 (-0.37%) CMC Crypto 200
1,439.60 -7.07 (-0.49%)
TEVA Jun 2024 16.000 call
| Previous close | 0.5600 |
| Open | 0.6700 |
| Bid | 0.4000 |
| Ask | 0.9300 |
| Strike | 16.00 |
| Expiry date | 2024-06-07 |
| Day's range | 0.6400 - 0.7400 |
| Contract range | N/A |
| Volume | |
| Open interest | 111 |
Business WireTeva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
TEL AVIV, Israel, June 04, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024. The presentation will begin at 8:00 A.M. Eastern Time.
ZacksTEVA Stock Rises 135% in a Year: What's Driving the Recovery?
TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
Business WireNew Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
TEL AVIV, Israel & PARSIPPANY, N.J., June 01, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program. Presentations include data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia
